NEWS
  • March 4, 2021 S1 Biopharma CEO Nick Sitchon to Participate in Maxim Group LLC Review of Late Stage Innovations in Women’s Health
  • December 1, 2019 Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women
  • January 4, 2019 S1 Biopharma to Participate in Panel Discussion on Investment Opportunities in China Hosted by Duane Morris and the Chinese Biopharmaceutical Association
  • January 4, 2019 S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys™ for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting
  • December 20, 2018 S1 Biopharma Granted Patents for Lorexys™ in Europe and Asia for Treatment of Hypoactive Sexual Desire Disorder
  • April 5, 2016 MedicalResearch.com | CEO Discusses Lorexys For Female Hypoactive Sexual Desire Disorder
  • February 19, 2016 Pharmaceutical Processing | In Development: HSDD Treatment for Women
  • February 19, 2016 PM360 | Will Lorexys Succeed Where Addyi Flopped?
  • December 8, 2015 S1 Biopharma and CKD Pharmaceuticals Announce Commercialization Agreement for Lorexys™ in South Korea for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Women
S1 Biopharma
  • COMPANY
    • ABOUT US
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • MEDICAL ADVISORY BOARD
  • PIPELINE
    • OREXA
    • LOREXYS
    • S1B-307
    • S1B-3006
  • A New Vision for addressing Sexual Wellness
    • SEXUAL DYSFUNCTION R&D
    • SCIENTIFIC PUBLICATIONS
    • PARTNERING
  • NEWSROOM
    • PRESS RELEASES
    • MEDIA COVERAGE
  • INVESTORS
    • LOGIN
  • CONTACT US

S1 Biopharma CEO Nick Sitchon to Participate in Maxim Group LLC Review of Late Stage Innovations in Women’s Health

March 4, 2021

Sitchon to highlight S1 Biopharma focus on central nervous system role in issues associated with sexual function and sexual wellness. NEW YORK, March 2, 2021 /PRNewswire/ — S1 Biopharma, Inc. (S1), a clinical stage company advancing therapies based on central…

Read more ›

Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women

December 1, 2019

Robert E. Pyke, MD, PhD, Anita H. Clayton, MD The Journal of Sexual Medicine. Volume 16, Issue 12, December 2019, Pages 1885-1894. Link

S1 Biopharma to Participate in Panel Discussion on Investment Opportunities in China Hosted by Duane Morris and the Chinese Biopharmaceutical Association

January 4, 2019

Event focused on cross-border deals between the U.S. and China in the health sciences sector to be held January 8, 2019 in San Francisco, coinciding with 37th Annual J.P. Morgan Healthcare Conference New York, NY – Jan. 4, 2019 –…

Read more ›

S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys™ for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting

January 4, 2019

New York, NY – Jan. 4, 2019 – S1 Biopharma, Inc. (S1) announced today that researchers will present an expanded analysis of data from the company’s Phase 2a clinical trial of Lorexys™ for the treatment of women with hypoactive sexual…

Read more ›

S1 Biopharma Granted Patents for Lorexys™ in Europe and Asia for Treatment of Hypoactive Sexual Desire Disorder

December 20, 2018

Newest patents significantly strengthen S1 intellectual property position New York, NY – December 20, 2018 – S1 Biopharma, Inc. (S1) announced today that the European Patent Office has granted a European Patent for the Company’s proprietary dual-mechanistic therapy Lorexys™ for…

Read more ›

MedicalResearch.com | CEO Discusses Lorexys For Female Hypoactive Sexual Desire Disorder

April 5, 2016

Pharmaceutical Processing | In Development: HSDD Treatment for Women

February 19, 2016

PM360 | Will Lorexys Succeed Where Addyi Flopped?

February 19, 2016

S1 Biopharma and CKD Pharmaceuticals Announce Commercialization Agreement for Lorexys™ in South Korea for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Women

December 8, 2015

Deal advances S1 Biopharma strategy for global commercialization of Lorexys. NEW YORK, Dec. 8, 2015 /PRNewswire/ — S1 Biopharma, Inc. a leading developer of first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women…

Read more ›

Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference

November 18, 2015

Mr. Sitchon will present an update on S1 Biopharma’s clinical stage development programs targeting treatment of diminished sexual desire in women and men. NEW YORK, Nov. 2, 2015 /PRNewswire/ — S1 Biopharma, Inc., a leading developer of first-in-class drugs for…

Read more ›

‹ Older posts

  • CONTACT US
  • SITE MAP
  • Terms of Use
  • © S1 biopharma Inc.
S1 Biopharma, Inc.
7 World Trade Center
250 Greenwich St.
46th Floor
New York City, NY 10007
Email: info@s1biopharma.com